Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Apr 1, 2015
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy

Mar 11, 2015
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results

View all »Events & Presentations

Jun 23, 2015
JMP Securities Life Sciences Conference

Investors